A phase i study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

W. Fiedler, S. Dedosso, Sara Cresta, J. Weidmann, Anna Tessari, M. Salzberg, B. Dietrich, H. Baumeister, Steffen Goletz, Luca Gianni, C. Sessa

Research output: Contribution to journalArticle

Abstract

Background A phase I open-label dose-escalation study was conducted to define the safety, tolerability, and pharmacokinetics (PK) of PankoMab-GEX, a glyco-optimised humanised IgG1, with high affinity to a novel tumour-specific glycopeptide epitope of MUC1 (TA-MUC1) with excellent preclinical anti-tumour activity. Patients and methods Seventy-four patients with advanced TA-MUC1-positive carcinomas received PankoMab-GEX intravenously every 3 (Q3W), 2 (Q2W), or 1 (QW) week in doses of 1-2200 mg in a three-plus-three dose-escalation design until disease progression (NCT01222624). Results No maximum tolerated dose was reached. Adverse events were mainly mild-to-moderate infusion-related reactions (IRRs) by the first infusion in 45% of patients. Only one dose-limiting toxicity, a grade III IRR, was observed. PankoMab-GEX exhibited linear PK over all doses. Mean terminal half-life was 189 ± 66 h (Q3W), without dose dependency. A target trough level ≥50 μg/mL was reached after one infusion with doses ≥1700 mg Q3W in 80% of patients. Clinical benefit in 60 evaluable patients included one complete response in a patient with ovarian cancer treated 483 d and confirmed disease stabilisation in 19 patients lasting a median (range) of 23 (10-109) weeks. All but two of the patients with clinical benefit had received a compounded total dose ≥700 mg over a 3-week period, including 8 of 12 (67%) patients with ovarian cancer. Conclusion PankoMab-GEX is safe, well tolerated, and showed promising anti-tumour activity in advanced disease. A phase IIb study is ongoing evaluating the efficacy of PankoMab-GEX as a maintenance therapy in advanced ovarian cancer.

Original languageEnglish
Pages (from-to)55-63
Number of pages9
JournalEuropean Journal of Cancer
Volume63
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Glycopeptides
Epitopes
Monoclonal Antibodies
Carcinoma
Neoplasms
Ovarian Neoplasms
Pharmacokinetics
PankoMab-GEX
Maximum Tolerated Dose
Half-Life
Disease Progression
Immunoglobulin G
Safety

Keywords

  • Glyco-optimised monoclonal antibody
  • Glycopeptide epitope
  • MUC1
  • Phase I
  • Solid tumours

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase i study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. / Fiedler, W.; Dedosso, S.; Cresta, Sara; Weidmann, J.; Tessari, Anna; Salzberg, M.; Dietrich, B.; Baumeister, H.; Goletz, Steffen; Gianni, Luca; Sessa, C.

In: European Journal of Cancer, Vol. 63, 01.08.2016, p. 55-63.

Research output: Contribution to journalArticle

Fiedler, W. ; Dedosso, S. ; Cresta, Sara ; Weidmann, J. ; Tessari, Anna ; Salzberg, M. ; Dietrich, B. ; Baumeister, H. ; Goletz, Steffen ; Gianni, Luca ; Sessa, C. / A phase i study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. In: European Journal of Cancer. 2016 ; Vol. 63. pp. 55-63.
@article{fa94990ee2c043f090d64cd929135e44,
title = "A phase i study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas",
abstract = "Background A phase I open-label dose-escalation study was conducted to define the safety, tolerability, and pharmacokinetics (PK) of PankoMab-GEX, a glyco-optimised humanised IgG1, with high affinity to a novel tumour-specific glycopeptide epitope of MUC1 (TA-MUC1) with excellent preclinical anti-tumour activity. Patients and methods Seventy-four patients with advanced TA-MUC1-positive carcinomas received PankoMab-GEX intravenously every 3 (Q3W), 2 (Q2W), or 1 (QW) week in doses of 1-2200 mg in a three-plus-three dose-escalation design until disease progression (NCT01222624). Results No maximum tolerated dose was reached. Adverse events were mainly mild-to-moderate infusion-related reactions (IRRs) by the first infusion in 45{\%} of patients. Only one dose-limiting toxicity, a grade III IRR, was observed. PankoMab-GEX exhibited linear PK over all doses. Mean terminal half-life was 189 ± 66 h (Q3W), without dose dependency. A target trough level ≥50 μg/mL was reached after one infusion with doses ≥1700 mg Q3W in 80{\%} of patients. Clinical benefit in 60 evaluable patients included one complete response in a patient with ovarian cancer treated 483 d and confirmed disease stabilisation in 19 patients lasting a median (range) of 23 (10-109) weeks. All but two of the patients with clinical benefit had received a compounded total dose ≥700 mg over a 3-week period, including 8 of 12 (67{\%}) patients with ovarian cancer. Conclusion PankoMab-GEX is safe, well tolerated, and showed promising anti-tumour activity in advanced disease. A phase IIb study is ongoing evaluating the efficacy of PankoMab-GEX as a maintenance therapy in advanced ovarian cancer.",
keywords = "Glyco-optimised monoclonal antibody, Glycopeptide epitope, MUC1, Phase I, Solid tumours",
author = "W. Fiedler and S. Dedosso and Sara Cresta and J. Weidmann and Anna Tessari and M. Salzberg and B. Dietrich and H. Baumeister and Steffen Goletz and Luca Gianni and C. Sessa",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.ejca.2016.05.003",
language = "English",
volume = "63",
pages = "55--63",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - A phase i study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

AU - Fiedler, W.

AU - Dedosso, S.

AU - Cresta, Sara

AU - Weidmann, J.

AU - Tessari, Anna

AU - Salzberg, M.

AU - Dietrich, B.

AU - Baumeister, H.

AU - Goletz, Steffen

AU - Gianni, Luca

AU - Sessa, C.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background A phase I open-label dose-escalation study was conducted to define the safety, tolerability, and pharmacokinetics (PK) of PankoMab-GEX, a glyco-optimised humanised IgG1, with high affinity to a novel tumour-specific glycopeptide epitope of MUC1 (TA-MUC1) with excellent preclinical anti-tumour activity. Patients and methods Seventy-four patients with advanced TA-MUC1-positive carcinomas received PankoMab-GEX intravenously every 3 (Q3W), 2 (Q2W), or 1 (QW) week in doses of 1-2200 mg in a three-plus-three dose-escalation design until disease progression (NCT01222624). Results No maximum tolerated dose was reached. Adverse events were mainly mild-to-moderate infusion-related reactions (IRRs) by the first infusion in 45% of patients. Only one dose-limiting toxicity, a grade III IRR, was observed. PankoMab-GEX exhibited linear PK over all doses. Mean terminal half-life was 189 ± 66 h (Q3W), without dose dependency. A target trough level ≥50 μg/mL was reached after one infusion with doses ≥1700 mg Q3W in 80% of patients. Clinical benefit in 60 evaluable patients included one complete response in a patient with ovarian cancer treated 483 d and confirmed disease stabilisation in 19 patients lasting a median (range) of 23 (10-109) weeks. All but two of the patients with clinical benefit had received a compounded total dose ≥700 mg over a 3-week period, including 8 of 12 (67%) patients with ovarian cancer. Conclusion PankoMab-GEX is safe, well tolerated, and showed promising anti-tumour activity in advanced disease. A phase IIb study is ongoing evaluating the efficacy of PankoMab-GEX as a maintenance therapy in advanced ovarian cancer.

AB - Background A phase I open-label dose-escalation study was conducted to define the safety, tolerability, and pharmacokinetics (PK) of PankoMab-GEX, a glyco-optimised humanised IgG1, with high affinity to a novel tumour-specific glycopeptide epitope of MUC1 (TA-MUC1) with excellent preclinical anti-tumour activity. Patients and methods Seventy-four patients with advanced TA-MUC1-positive carcinomas received PankoMab-GEX intravenously every 3 (Q3W), 2 (Q2W), or 1 (QW) week in doses of 1-2200 mg in a three-plus-three dose-escalation design until disease progression (NCT01222624). Results No maximum tolerated dose was reached. Adverse events were mainly mild-to-moderate infusion-related reactions (IRRs) by the first infusion in 45% of patients. Only one dose-limiting toxicity, a grade III IRR, was observed. PankoMab-GEX exhibited linear PK over all doses. Mean terminal half-life was 189 ± 66 h (Q3W), without dose dependency. A target trough level ≥50 μg/mL was reached after one infusion with doses ≥1700 mg Q3W in 80% of patients. Clinical benefit in 60 evaluable patients included one complete response in a patient with ovarian cancer treated 483 d and confirmed disease stabilisation in 19 patients lasting a median (range) of 23 (10-109) weeks. All but two of the patients with clinical benefit had received a compounded total dose ≥700 mg over a 3-week period, including 8 of 12 (67%) patients with ovarian cancer. Conclusion PankoMab-GEX is safe, well tolerated, and showed promising anti-tumour activity in advanced disease. A phase IIb study is ongoing evaluating the efficacy of PankoMab-GEX as a maintenance therapy in advanced ovarian cancer.

KW - Glyco-optimised monoclonal antibody

KW - Glycopeptide epitope

KW - MUC1

KW - Phase I

KW - Solid tumours

UR - http://www.scopus.com/inward/record.url?scp=84974621186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974621186&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2016.05.003

DO - 10.1016/j.ejca.2016.05.003

M3 - Article

VL - 63

SP - 55

EP - 63

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -